Impairment of the in vitro Release of Carbamazepine from Tablets
Carbamazepine belongs to the class II biopharmaceutical classification system (BCS) which is characterized by a high per-oral dose, a low aqueous solubility and a high membrane permeability. The bioavailability of such a drug is limited by the dissolution rate. The present study deals with the formu...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
2010-08-01
|
Series: | Bosnian Journal of Basic Medical Sciences |
Subjects: | |
Online Access: | http://www.bjbms.org/ojs/index.php/bjbms/article/view/2693 |
id |
doaj-1bcbea8fc13e4f4592e51e4ba47f4025 |
---|---|
record_format |
Article |
spelling |
doaj-1bcbea8fc13e4f4592e51e4ba47f40252020-11-25T01:02:25ZengAssociation of Basic Medical Sciences of Federation of Bosnia and HerzegovinaBosnian Journal of Basic Medical Sciences1512-86011840-48122010-08-0110310.17305/bjbms.2010.2693417Impairment of the in vitro Release of Carbamazepine from TabletsAlija Uzunović0Edina Vranić1Šeherzada Hadžidedić2Agency for Medical Products and Medical Devices of Bosnia and HerzegovinaDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of SarajevoAgency for Medical Products and Medical Devices of Bosnia and HerzegovinaCarbamazepine belongs to the class II biopharmaceutical classification system (BCS) which is characterized by a high per-oral dose, a low aqueous solubility and a high membrane permeability. The bioavailability of such a drug is limited by the dissolution rate. The present study deals with the formulations of immediate release tablets of poorly soluble carbamazepine. As model tablets for this investigation, two formulations (named “A” and “B” formulations) of carbamazepine tablets labeled to contain 200 mg were evaluated. The aim of this study was to establish possible differences in dissolution profile of these two formulations purchased from the local market. The increased crystallinity together with enlarged particle size, enhanced aggregation and decreased wettability of the drug, resulted in insufficient dissolution rate for formulation “B’.’ From the dissolution point of view, this formulation was inferior to the formulation “A, due to the solubilization effect. http://www.bjbms.org/ojs/index.php/bjbms/article/view/2693carbamazepineimpairmentin vitro release |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Alija Uzunović Edina Vranić Šeherzada Hadžidedić |
spellingShingle |
Alija Uzunović Edina Vranić Šeherzada Hadžidedić Impairment of the in vitro Release of Carbamazepine from Tablets Bosnian Journal of Basic Medical Sciences carbamazepine impairment in vitro release |
author_facet |
Alija Uzunović Edina Vranić Šeherzada Hadžidedić |
author_sort |
Alija Uzunović |
title |
Impairment of the in vitro Release of Carbamazepine from Tablets |
title_short |
Impairment of the in vitro Release of Carbamazepine from Tablets |
title_full |
Impairment of the in vitro Release of Carbamazepine from Tablets |
title_fullStr |
Impairment of the in vitro Release of Carbamazepine from Tablets |
title_full_unstemmed |
Impairment of the in vitro Release of Carbamazepine from Tablets |
title_sort |
impairment of the in vitro release of carbamazepine from tablets |
publisher |
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina |
series |
Bosnian Journal of Basic Medical Sciences |
issn |
1512-8601 1840-4812 |
publishDate |
2010-08-01 |
description |
Carbamazepine belongs to the class II biopharmaceutical classification system (BCS) which is characterized by a high per-oral dose, a low aqueous solubility and a high membrane permeability. The bioavailability of such a drug is limited by the dissolution rate. The present study deals with the formulations of immediate release tablets of poorly soluble carbamazepine. As model tablets for this investigation, two formulations (named “A” and “B” formulations) of carbamazepine tablets labeled to contain 200 mg were evaluated. The aim of this study was to establish possible differences in dissolution profile of these two formulations purchased from the local market.
The increased crystallinity together with enlarged particle size, enhanced aggregation and decreased wettability of the drug, resulted in insufficient dissolution rate for formulation “B’.’ From the dissolution point of view, this formulation was inferior to the formulation “A, due to the solubilization effect.
|
topic |
carbamazepine impairment in vitro release |
url |
http://www.bjbms.org/ojs/index.php/bjbms/article/view/2693 |
work_keys_str_mv |
AT alijauzunovic impairmentoftheinvitroreleaseofcarbamazepinefromtablets AT edinavranic impairmentoftheinvitroreleaseofcarbamazepinefromtablets AT seherzadahadzidedic impairmentoftheinvitroreleaseofcarbamazepinefromtablets |
_version_ |
1725205089733312512 |